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ABSTRACT
Denosumab has been used successfully to treat disease‐associated osteoclast overactivity, including giant cell tumor of bone.
Given its mechanism of action, denosumab is a potent potential treatment of other osteoclast bone dysplasias including central
giant cell granuloma (CGCG), aneurysmal bone cyst (ABC), and cherubism. Relatively little is known about the safety and efficacy
of denosumab in patients with these conditions, especially in children. We report on 3 pediatric patients treated with denosumab
over a 3‐year period at UCLA Medical Center (Los Angeles and Santa Monica, CA, USA): a 12‐year‐old with recurrent ABC of the
pelvis, a 14‐year‐old with CGCG of the mandible, and a 12‐year‐old with cherubism. All were started on a 1‐year course of 15 doses
120mg s.c., given monthly with two loading doses on day 8 and 15. All patients demonstrated rapid and pronounced clinical
improvement while on denosumab, including a significant reduction in pain and sclerosis of lytic lesions on radiographs. Within 1
month of initiating therapy, 2 patients experienced hypocalcemia (Common Terminology Criteria for Adverse Events [CTCAE]
grade 2) and hypophosphatemia, with 1 patient experiencing symptoms. One patient went on to experience symptomatic
rebound hypercalcemia (CTCAE grade 4) 5 months after completing therapy, requiring bisphosphonates and calcitonin. For the
second patient, we developed a schedule to wean denosumab involving the progressive lengthening of time between doses from
1 to 4 months in 1‐month increments before cessation. We found that denosumab therapy results in significant clinical and
radiographic improvement for pediatric patients with nonresectable ABC, CGCG, and cherubism. Problems with serum calcium
may be more common in younger patients, with symptomatic and protracted rebound hypercalcemia after cessation of therapy
the most significant. We present a potential solution to this problem with progressive spacing of doses. Potential serious adverse
events from alterations in calcium homeostasis should be explored in prospective clinical trials. © 2019 The Authors. JBMR Plus
published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.
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Introduction
Denosumab, a monoclonal antibody against RANKL, hasbeen used successfully to treat diseases associated with
osteoclast overactivity, including giant cell tumor of bone
(GCTB), osteoporosis, and lytic lesions associated with bony
metastases.(1–3) Increasingly, denosumab has been used off‐
label for other disorders of bone thought to result, at least in
part, from similar osteoclastic pathology. These include central
giant cell granuloma (CGCG), aneurysmal bone cyst (ABC),
cherubism, and fibrous dysplasia (FD).
Cherubism is characterized by focal resorption and replacement
with proliferative fibro‐osseous masses of the maxillary and
mandibular bones. A gain‐of‐function mutation in SH3BP2 has
been identified as a driver of cherubism; this mutation leads to
osteoclastogenesis in the presence of RANKL and TNF‐α through
interactions with a variety of proteins in hemopoietic progenitor
cells.(4) Similarly, osteoclast multinucleated giant cells have been
identified in CGCG.(5) These same cells have been found in
pathological specimens of ABCs, though it is hypothesized they
are reactive in nature.(6,7) Finally, excess osteoclastogenesis has
been consistently identified in patients with FD.(8) The potential
role of multinucleated giant cells in these conditions has led to
the limited application of denosumab in their treatment.
No clinical trials of denosumab have been published, and
there are no ongoing clinical trials listed on Clinicaltrials.gov for
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these groups of patients. Cases have been reported for the use
of denosumab in ABC,(7,9–13) CGCG,(14–18) cherubism,(19) and
FD(20,21) for 8, 10, 1, and 3 patients, respectively. Of these,
5 patients were <16 years old when they began treatment.
Although this therapy appears to be equally effective in
younger patients based on this small sample, problems with
calcium regulation may be more prevalent.
Though the safety of denosumab in adults and skeletally
mature populations has been studied in patients with GCTB,
little information exists on possible side‐effects in skeletally
immature patients or patients with other pathology. These
known side‐effects in adult populations include hypocal-
cemia (5%), hypophosphatemia (3%), back and or extremity
pain (1%), and osteonecrosis of the jaw (1%).(22) In pediatric
patients, there have been two reports of hypercalcemia. In
one 9‐year‐old patient with CGCG of the mandible, hyper-
calcemia was asymptomatic and resolved without interven-
tion.(17) In another 9‐year‐old patient with FD of the femur,
severe symptomatic hypercalcemia developed after cessa-
tion of treatment requiring i.v. calcitonin and bisphospho-
nate therapy, returning to normal serum calcium levels after
approximately 5 months.(21)
The use of denosumab in pediatric patients remains poorly
studied; consequently clinicians are understandably reluctant
to use this therapy in this population. Here we present our
experience treating 3 pediatric patients off‐label with deno-
sumab for a diagnosis of CGCG, ABC, or cherubism. We report a
similar case of rebound hypercalcemia as reported pre-
viously,(21) as well as our strategy for preventing this in our
most recently treated patient.
Patients and Methods
All patients were treated at UCLA Medical Centers in Los
Angeles and Santa Monica, California, USA. Diagnosis was
established using tissue histopathology, radiographic appear-
ance, and clinical history. All patients weighed over 40 kg when
therapy was initiated, and all were started on an adult dose of
120mg s.c. every 4 weeks, with additional loading doses on day
8 and 15 in accordance with the dosing schedule established
for adult patients.(2,3) The first patient, with recurrent ABC of the
pelvis, started treatment when she was 12 years old, receiving
14 doses. The second patient, with CGCG of mandible, began
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Fig. 1. Patient laboratory studies over the duration of denosumab therapy for serum calcium (A), alkaline phosphate (B), ionized calcium (C), and
phosphate (D). Dashed lines represent laboratory reference ranges at the University of California Los Angeles.
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therapy when he was 14 years old and received 15 doses. The
third patient, with cherubism, began therapy when she was 12
years old and has received 13 doses to date. No patient had
clinical or radiological signs of a wider syndrome.
All patients received daily calcium carbonate and vitamin D
supplementation, initially with 500mg calcium carbonate and
1000 units of vitamin D3 daily and increased as necessary. No
restrictions were placed on diet or activity for patients with
these pathologies. For the patients with extremity tumors, full
weight‐bearing is allowed, but moderate‐to‐high impact
exercise and sports is discouraged. Patient follow‐up schedules,
laboratory studies, and imaging studies were not standardized
and were established and administered at the discretion of the
providers managing treatment. Plain film X‐rays were the
standard imaging modality; CT and MRI were utilized where
appropriate.
Results
Patient 1: recurrent aneurysmal bone cyst of the pelvis
This patient was a 10‐year‐old female who was diagnosed
with an extensive ABC of the pelvis. She underwent
curettage and bone grafting; she tolerated the procedure
well. However, 2 years later she presented with pain
following a fall; it was found that her pelvic ABC had
recurred, hence she underwent a second curettage and
bone grafting. Histology revealed a cystic bone lesion with
connective tissue, reactive woven bone, and hemorrhage,
with fibroblasts and scattered osteoclast‐type giant cells
noted. Her case was reviewed by a multidisciplinary
musculoskeletal tumor board: The consensus was that an
additional ABC was present, and that the lesion was not
amenable to repeat curettage without significant potential
morbidity. At a weight of 40 kg, she initiated denosumab
therapy 1 month prior to her 13th birthday. She received
denosumab on a monthly schedule with a day 8 loading
dose (patient missed a day 15 loading dose) of 120 mg over
the course of a year.
She achieved excellent clinical response and showed
sclerosis of lesions at most recent imaging (Fig. 2). Plain film
radiography showed impressive sclerosis of her cysts, with no
increase in size (Fig. 2C). Hip pain that was present prior to
denosumab initiation resolved rapidly over the course of the
first month of treatment with denosumab. She continues to be
pain‐free in her hip and has had no issues ambulating in the 13
months since discontinuation of denosumab.
Toxicities associated with treatment included Common
Terminology Criteria for Adverse Events (CTCAE v4.0) grade 2
hypocalcemia at the start of therapy and rebound grade 3 to 4
hypercalcemia upon cessation of denosumab, which are
described here. In the first month of therapy, the patient
experienced asymptomatic hypocalcemia (Fig. 1A, C) with
associated hypophosphatemia (Fig. 1D). Her serum calcium
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Fig. 2. Patient with aneurysmal bone cyst of pelvis. (A, B) Judet plain film and sagittal CT before denosumab therapy and after two prior surgical
interventions (C, D) and posteroanterior pelvis plain film and sagittal CT after denosumab therapy.
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normalized within 2 months without any intervention. Five
months after her final dose, she was admitted with serum
calcium of 15.5 mg/dL (Fig. 1A, C) and symptoms of hypercal-
cemia, including severe diffuse abdominal pain, nausea, and
vomiting. She had no laboratory or radiological evidence of
nephrocalcinosis. She required bisphosphonates, furosemide,
and calcitonin to lower her serum calcium levels. After
discharge, her serum calcium had returned to normal at 9.6.
She experienced two episodes of asymptomatic hypercalcemia
the following month to 11.6 and 11.5mg/dL, respectively, that
corrected with 2 weeks of furosemide therapy. She has
subsequently had normal serum calcium levels.
Patient 2: central giant cell granuloma of the mandible
This patient presented with a progressive mandibular mass over
the course of 4 years that was diagnosed as CGCG at
14 years of age. He experienced a recurrence of CGCG with
free‐floating lower teeth and severe pain with mastication. Given
the progressive severe pain, failure of intralesional steroids and
calcitonin, and significant functional limitation and progressive
growth of the mass, he was considered for a partial mandibu-
lectomy. Because of the potential morbidity from this surgical
procedure, denosumab was discussed as a potential way to
avoid or delay the need for mandibulectomy. He initiated
denosumab therapy when he was 14 years old, and received
monthly denosumab with loading doses at day 8 and day 15 for
a total of 15 doses of 120mg over the course of a year. He
weighed 56 kg at the start of therapy. He did not experience any
complications while on denosumab or after the completion of
therapy, and his laboratory studies did not demonstrate any
marked abnormalities in serum calcium levels (Fig. 1A), and
serum alkaline phosphatase was appropriately suppressed to
below the normal range while on therapy (Fig. 1B).
He had an excellent clinical and radiological response (Fig. 3).
Within 1 month of starting denosumab, he had complete
resolution of severe mandibular pain; achieved fully functional
mastication; and dentition, which was loose and painful,
became fixed in the mandible. As with patient 1, serum
alkaline phosphatase decreased appropriately with therapy.
Patient 3: cherubism
This patient was diagnosed with cherubism at 5 years of age,
and she experienced refractory progressive disease. She
presented with severe pain in her bilateral mandibles with
uncontrolled oral–gingival bleeding, resulting in numerous
emergency room visits, opioid use, and oral procoagulants
(aminocaproic acid). She started denosumab therapy as a
12 year old. She weighed 42 kg at the start of therapy.
Within 1 month of starting denosumab, her pain had
completely resolved as did her oral bleeding. After 6 months
of therapy, she showed an excellent radiographic response
with increased sclerosis in the severely osteolytic mandibular
and maxillary lesions (Fig. 4).
Toxicity associated with treatment included serious adverse
event CTCAE grade 3 hypocalcemia requiring hospitalization
(Fig. 1A, C); symptoms included tingling and numbness in her
hands, as well as generalized weakness. She had concomitant
hypophosphatemia to 2.6 mg/dL (Fig. 1D) with a normal serum
PTH of 48 pg/mL (range 11 to 51 pg/mL). In contrast to patients
1 and 2, serum alkaline phosphatase initially increased in
response to denosumab therapy before subsequently de-
creasing (Fig. 1B).
After this episode, denosumab was dose‐reduced by 50% to
60mg monthly. After 10 months of therapy, she was started on
a weaning schedule to gradually discontinue denosumab.
She received her 11th dose 2 months after her 10th, and her
12th dose 2 months after that. Her 13th dose is planned for
3 months after her 12th; her final dose will be 4 months after
the previous dose.
Discussion
In this case series, we describe the off‐label use of denosumab
in 3 pediatric patients with recurrent ABC, CGCG, and
cherubism. All patients demonstrated a robust and rapid
clinical and radiographic response to denosumab. However, 2
patients experienced hypocalcemia following initiation of
therapy, with 1 patient progressing to symptomatic hypercal-
cemia requiring inpatient hospitalization, as well as i.v.
bisphosphonate and calcitonin therapy to normalize serum
◼ 4 UPFILL‐BROWN ET AL. JBMR Plus (WOA)
Fig. 3. Patient with central giant cell granuloma of the mandible (A)
before denosumab, (B) after 6 months of therapy, and (C) after 10 months
of therapy.
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calcium levels. This is similar to a pediatric case that has been
described previously.(21) Our proposed method of avoiding
hypercalcemia in pediatric patients is by gradually increasing
the time between doses before completely terminating
therapy.
Previous studies have used different dosing schedules for
pediatric patients. Examples include a starting dose of 1.2mg/kg,
increasing by 0.1 kg/mg weekly, to a target dose of 1.6mg/kg
given monthly after the loading dose.(12) Others have used a
starting dose of 1mg/kg, increasing by 0.25mg/kg every
3 months to a final dose 1.75mg/kg.(21) Others have opted for a
surface area‐based adjustment of 70mg/m2 in children.(7) One
9‐year‐old pediatric patient was treated with a full adult dose of
120mg for 18 months.(17) Recently at our institution, we have
eliminated loading doses of denosumab to avoid hypocalcemia
with the initiation of therapy.
In the 3 patients described here, hypocalcemia and
hypercalcemia were the primary complications noted. In
the 22 other published cases of off‐label denosumab use in
pediatric and adult patients (Table 1),(7,9–21) complications
described include symptomatic and asymptomatic hyper-
calcemia (2 patients, 1 with FD, 1 with CGCG), asymptomatic
hypocalcemia (3 patients, 2 with FD, 1 with ABC), asympto-
matic hypophosphatemia (3 patients with FD), extremity/
skeletal pain (1 patient with CGCG), and delayed wound
healing (1 patient with CGCG). In the only other case of
symptomatic hypercalcemia described previously, also in a
pediatric patient, the hypercalcemia was preceded by
hypophosphatemia and increased serum PTH upon initia-
tion of therapy. Our patient who experienced rebound
hypercalcemia initially experienced asymptomatic hypocal-
cemia and hypophosphatemia upon initiation of therapy.
Rebound hypercalcemia may be related to elevated PTH
and PTH receptors in people with recently closed growth
plates or certain pathologies. Unfortunately, we cannot
correlate this theory with the cases described here as serum
PTH levels were not routinely measured. In addition,
hypophosphatemia and/or hypocalcemia upon initiation
of therapy may signal potential problems with rebound
hypercalcemia upon cessation of therapy. Moreover, in the
patient with cherubism, hypocalcemia was associated with
an inappropriately normal serum PTH concentration. This
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Fig. 4. Patient with cherubism (A, C). Representative sagittal and coronal images before initiation of denosumab (B, D) and after 6 months of therapy.
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particular patient also displayed higher serum alkaline
phosphatase levels at baseline and an initial increase—
rather than the typically observed decrease—in alkaline
phosphatase activity in response to denosumab. Although
further studies are warranted to determine whether these
findings are consistent in patients with SH3BP2 mutations,
previous reports suggest that cherubism may be associated
with impaired osteoblast function and altered PTHrP‐PTHrP
receptor interactions,(23,24) suggesting that an underlying
disease mutation may contribute to accentuated changes in
mineral ion homeostasis in some patients.
Conclusions
In the cases described here, denosumab therapy results in
significant clinical and radiographic improvement for pediatric
patients with ABC, CGCG, and cherubism. In younger patients,
problems with serum calcium levels both at the initiation of
treatment and at discontinuation may be more common, with
symptomatic and protracted rebound hypercalcemia after
cessation of therapy the most significant. We present a
potential solution to this problem involving the progressive
lengthening of time between doses from 1 to 4 months in
1‐month increments before final cessation of denosumab. We
also recommend potentially reducing or eliminating loading
doses to avoid hypocalcemia with the initiation of therapy.
Denosumab may be a viable therapeutic option for children
with nonresectable osteoclastic bone dysplasias such as ABC,
CGCG, cherubism, and FD. However, because of potential
serious adverse events from alterations in calcium home-
ostasis, this option should be explored carefully in prospective
clinical trials of denosumab in children with the aforemen-
tioned diseases. The incidence of treatment‐related and
treatment‐emergent adverse events with rebound hypercal-
cemia and hypocalcemia in our patients warrants careful
oversight and frequent serial monitoring when administering
denosumab and discontinuing denosumab in children and
adolescents.
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